[go: up one dir, main page]

JP2850262B2 - How to maintain a stable plasmid - Google Patents

How to maintain a stable plasmid

Info

Publication number
JP2850262B2
JP2850262B2 JP5472790A JP5472790A JP2850262B2 JP 2850262 B2 JP2850262 B2 JP 2850262B2 JP 5472790 A JP5472790 A JP 5472790A JP 5472790 A JP5472790 A JP 5472790A JP 2850262 B2 JP2850262 B2 JP 2850262B2
Authority
JP
Japan
Prior art keywords
medium
yeast
plasmid
histidine
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP5472790A
Other languages
Japanese (ja)
Other versions
JPH03254685A (en
Inventor
一昭 北野
正徳 中津
正人 栗山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP5472790A priority Critical patent/JP2850262B2/en
Publication of JPH03254685A publication Critical patent/JPH03254685A/en
Application granted granted Critical
Publication of JP2850262B2 publication Critical patent/JP2850262B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

【発明の詳細な説明】 産業上の利用分野 本発明は、遺伝子組換え酵母を利用して異種蛋白質を
生産する際に、酵母に組換えプラスミドを安定に保持さ
せる方法に関する。
Description: TECHNICAL FIELD The present invention relates to a method for stably retaining a recombinant plasmid in yeast when producing a heterologous protein using genetically modified yeast.

従来の技術 遺伝子組換え技術を用いて生理活性物質を生産する際
に宿主菌体内で組換えプラスミドが安定に保持されるこ
とが、その高い生産性を保持する上でも、また生産され
る物質の品質を保証する上でも必須である。酵母を宿主
とする遺伝子組換え体においてもプラスミドを安定に保
持させるために種々の試みが行われてきた。その1つは
目的遺伝子を染色体に組込ませる方法であるが、この方
法では細胞当りの目的産物産生遺伝子のコピー数が少な
く、必ずしも十分な生産性が得られない。2μmプラス
ミドの複製開始点を持つプラスミドベクターは、2μm
プラスミドを持たない酵母(cir0株)に比べ、2μmプ
ラスミドを持つ酵母(cir+株)中でより安定に保たれる
が、ベクターの占める割合がクローン毎に著しく異なる
と云う問題点がある。染色体由来の複製開始点ARSを持
つプラスミドはコピー数が多いが、宿主内での安定性が
悪い。この点を解決するために2μmの複製開始点とAR
Sを同時に持つ発現プラスミドも開発されている。
Conventional technology When a biologically active substance is produced using gene recombination technology, the stable maintenance of the recombinant plasmid in the host cells is important for maintaining the high productivity and for the production of the substance. It is also essential to guarantee quality. Various attempts have been made to stably maintain a plasmid even in a recombinant using yeast as a host. One of them is a method of integrating a target gene into a chromosome. However, in this method, the number of copies of a target product-producing gene per cell is small, and sufficient productivity cannot always be obtained. A plasmid vector having a replication origin of 2 μm plasmid is 2 μm
Compared with a yeast having no plasmid (strain cir 0 ), it is more stably maintained in a yeast having a 2 μm plasmid (cir + strain), but there is a problem that the proportion occupied by the vector differs significantly from clone to clone. Plasmids with a chromosomal origin of replication ARS have high copy number but poor stability in the host. In order to solve this point, a replication start point of 2 μm and AR
An expression plasmid with S has also been developed.

発明が解決しようとする課題 しかし、従来の知見だけでは、目的遺伝子の発現プラ
スミドを宿主酵母内で必ずしも安定に保持できるとは限
らず、更に新しい技術の開発が必須である。
Problems to be Solved by the Invention However, conventional knowledge alone cannot always stably maintain an expression plasmid for a target gene in a host yeast, and further development of a new technology is essential.

問題点を解決するための手段 上記の事情に鑑み本発明者らは、培地に添加すること
により酵母菌体内にプラスミドを安定に保持させること
ができる物質について種々検討を行った結果、ヒスチジ
ンを添加した培地で組換え体を培養することによりプラ
スミドが安定に保持できることを発見し、更に種々検討
を重ねた結果、本発明を完成するに至った。
Means for Solving the Problems In view of the above circumstances, the present inventors have conducted various studies on substances capable of stably retaining a plasmid in yeast cells by adding the medium, and as a result, histidine was added. It has been discovered that the plasmid can be stably maintained by culturing the recombinant in the obtained medium, and as a result of various studies, the present invention has been completed.

すなわち、本発明は、組換えプラスミドを保持する酵
母を、150mg/l以上のヒスチジンを添加した培地で培養
することを特徴とする、酵母菌体内で組換えプラスミド
を安定に保持させる方法を提供するものである。
That is, the present invention provides a method for stably maintaining a recombinant plasmid in yeast cells, comprising culturing a yeast holding the recombinant plasmid in a medium to which 150 mg / l or more histidine has been added. Things.

本発明で使用される組換えプラスミドとしては、YRp
型やYEp型のベクターまたはその両方を持つ酵母内で複
製可能なプラスミドが挙げられる。より具体的には修飾
B型肝炎ウイルス表面抗原(HBsAg)P31蛋白質の酵母発
現プラスミドpGLD P31-RcT(特開昭63-109795号公
報),ヒトリゾチームの酵母菌体外発現プラスミドpGEL
125(特開昭64-10986号公報)などが有利に用いられ
る。
As the recombinant plasmid used in the present invention, YRp
And a plasmid capable of replicating in yeast having a vector of the type or YEp type or both. More specifically, a modified hepatitis B virus surface antigen (HBsAg) P31 protein yeast expression plasmid pGLD P31-RcT (JP-A-63-109795) and a human lysozyme yeast extracellular expression plasmid pGEL
125 (JP-A-64-10986) and the like are advantageously used.

本発明に使用される宿主としては、サッカロミセス・
セレビシエ(Saccharomyces cerevisiae),より具体的
にはサッカロミセス・セレビシエAH22R-(leu2 his4 ca
nl cir+ pho80)[Proc.Ntl.Acad.Sci.USA,80,1(198
3)]またはその誘導株などが用いられ、公知の方法[H
innen,A,ら,Proc.Natl.Acad.Sci.USA,75,1927(197
8)]またはそれに準ずる方法によって組換えプラスミ
ドが導入される。
As the host used in the present invention, Saccharomyces
Cerevisiae (Saccharomyces cerevisiae), more specifically Saccharomyces cerevisiae AH22R - (leu2 his4 ca
nl cir + pho80) [Proc.Ntl.Acad.Sci.USA, 80 , 1 (198
3)] or a derivative thereof and the like, and a known method [H
innen, A, et al., Proc. Natl. Acad. Sci. USA, 75 , 1927 (197
8)] or a recombinant plasmid is introduced by a method analogous thereto.

かくして得られた酵母組換え体を培養するに際し、ヒ
スチジンを添加した培地が用いられるが、ヒスチジンと
してはL−ヒスチジンまたはDL−ヒスチジンおよびそれ
らの含有物が用いられる。その添加量はL−ヒスチジン
として150mg/lないし1000mg/l、より好ましくは200mg/l
ないし500mg/lである。組換えプラスミド中の遺伝子に
よってコードされる目的物質を生産させるための酵母組
換え体の培養の際および継代のための培養の際には上記
量のヒスチジンが培地に添加される。目的物質を生産さ
せるための培養に先立ち、酵母組換え体の増殖のための
前培養を行ってもよい。前培養に用いられる培地へのヒ
スチジンの添加量は上記の添加量より少量でもよいい
(例えば、L−ヒスチジンとして100mg/lないし150mg/l
程度)が、好ましくは上記の量(150mg/lないし1000mg/
l,より好ましくは200mg/lないし500mg/l)のL−ヒスチ
ジンが添加された培地が前培養にも用いられる。培地と
しては自体公知の液体または寒天培地が用いられるが、
たとえばバークホルダー氏の最小培地[Bulkholder.P.
R.:Am.J.Bot.30,206(1943)]やバクト・イースト・ニ
トローゲン・ベース(Difco社)が挙げられる。組換え
体が栄養要求性を示す場合には必要に応じて要求物が添
加されるが、更に場合によっては少量の天然物,たとえ
ばカザミノ酸,酵母エキス,麦芽エキス等を添加するこ
とができる。
When culturing the yeast recombinant thus obtained, a medium to which histidine is added is used. As histidine, L-histidine or DL-histidine and their contents are used. The added amount is 150 mg / l to 1000 mg / l as L-histidine, more preferably 200 mg / l.
Or 500 mg / l. The above amount of histidine is added to the medium when culturing a yeast recombinant to produce the target substance encoded by the gene in the recombinant plasmid and during culturing for subculture. Prior to culture for producing the target substance, preculture for propagation of the yeast recombinant may be performed. The amount of histidine to be added to the medium used for the preculture may be smaller than the above-mentioned amount (for example, 100 mg / l to 150 mg / l as L-histidine).
Degree), preferably the above amount (150 mg / l to 1000 mg /
(preferably 200 mg / l to 500 mg / l) of L-histidine is also used for the preculture. As the medium, a liquid or agar medium known per se is used,
For example, Barkholder's minimal medium [Bulkholder.P.
R.:Am.J.Bot. 30 , 206 (1943)] and Bacto East Nitrogen Base (Difco). If the recombinant shows auxotrophy, the required product is added as needed. In some cases, a small amount of a natural product such as casamino acid, yeast extract or malt extract can be added.

酵母の組換え体の培養は通常15℃〜40℃,好ましくは
20〜35℃で、1〜5日間,好ましくは2〜4日間行な
い、必要により通気や撹拌を加えることもできる。
Culture of yeast recombinants is usually 15 ° C to 40 ° C, preferably
The reaction is carried out at 20 to 35 ° C. for 1 to 5 days, preferably 2 to 4 days, and if necessary, aeration and stirring can be added.

目的物質が酵母組換え体の菌体外に分泌される場合、
培養後培養上清を自体公知の各種の分離精製法に付し目
的物質を単離精製することができる。目的物質が酵母組
換え体の菌体外の分泌されない場合には、培養後、公知
の方法で菌体を集め、ザイモリエース[キリンビール
(株)製]による溶菌あるいは超音波処理やガラスビー
ズなどによる機械的破砕によって菌体を破壊し、目的物
質を抽出した後、抽出液を自体公知の各種の分離精製法
に付し目的物質を単離精製することができる。得られた
精製製品は従来の方法で生産された標品と同様,目的
(例えばヒトの疾病の治療、予防等)に応じて用いるこ
とができる。
When the target substance is secreted out of the yeast recombinant cells,
After the culture, the culture supernatant can be subjected to various known separation and purification methods to isolate and purify the target substance. If the target substance is not secreted outside the cells of the yeast recombinant, the cells are collected after culturing, and then lysed with Zymolyase [manufactured by Kirin Brewery Co., Ltd.], or subjected to sonication or glass beads. After the cells are destroyed by mechanical disruption and the target substance is extracted, the extract can be subjected to various separation and purification methods known per se to isolate and purify the target substance. The obtained purified product can be used according to the purpose (for example, treatment or prevention of a human disease) in the same manner as a sample produced by a conventional method.

実施例 以下に実施例を挙げて本発明を更に具体的に説明する
が、本発明はこれらによって何ら限定されるものではな
い。
EXAMPLES Hereinafter, the present invention will be described more specifically with reference to Examples, but the present invention is not limited thereto.

サッカロミセス・セレビシエ(Saccharomyces cerevi
siae)AH22R-/pGLD P31-RcTは財団法人発酵研究所(IF
O)にIFO 10206として寄託され、また日本国通商産業省
工業技術院微生物工業技術研究所(FRI)にFERM BP-105
9として特許手続上の微生物の寄託の国際的承認に関す
るブダペスト条約(ブダペスト条約)に基づき寄託され
ている。
Saccharomyces cerevi
siae) AH22R - / pGLD P31- RcT the Institute for Fermentation (IF
O) was deposited as IFO 10206, and FERM BP-105 was registered with the Research Institute of Microbial Technology (FRI) of the Ministry of International Trade and Industry of Japan.
No. 9 has been deposited under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms in Patent Procedures (Budapest Treaty).

サッカロミセス・セレビシエ(Saccharomyces cerevi
siae)AH22R-/pGEL125はIFOにIFO 10211として寄託さ
れ、またFRIにFERM BP-1345としてブダペスト条約に基
づき寄託されている。
Saccharomyces cerevi
siae) AH22R - / pGEL125 was deposited as IFO 10211 in IFO, also has been deposited under the Budapest Treaty as FERM BP-1345 to FRI.

実施例1 修飾HBsAg P31蛋白質産生組換え体サッカロミセス・
セレビシエAH22R-/pGLD P31-RcTを2l容三角フラスコに
仕込んだ前培養培地1(1当り、グルコース100g,
リン酸1水素カリウム3g,L−アスパラギン4g,L−ヒスチ
ジン100mg,硫酸マグネシウム500mg,塩化カルシウム330m
g,ヨウ化カリウム0.1mg,硫酸第1鉄2.5mg,硫酸銅0.4mg,
硫酸マンガン0.4mg,リンモリブデン酸アンモニウム0.2m
g,硫酸亜鉛3.1mg,イノシトール30mg,チアミン0.6mg,ピ
リドキシン0.6mg,パントテン酸カルシウム0.6mg,ナイア
シン0.6mg,ビオチン0.006mgを含む)に接種し、30℃で
3日間培養したのち、その前培養液200mlを5l容醗酵槽
に仕込んだ2.5lの生産用培地[1当り、庶糖120g,リ
ン酸1水素ナトリウム2.5g,リン酸2水素カリウム0.5g,
硫酸アンモニウム2g,硫酸マグネシウム0.5g,塩化カルシ
ウム0.33g,硫酸第1鉄10mg,硫酸マンガン10mg,硫酸亜鉛
10mg,ヨウ化カリウム0.1mg,イノシトール90mg,塩酸チア
ミン1.8mg,塩酸ピリドキシン1.8mg,ニコチン酸1.8mg,パ
ントテン酸カルシウム1.8mg,ビオチン0.018mgを含む]
に、L−ヒスチジンを100mg/l,150mg/l,200mg/l,400mg/
lとなるようにそれぞれ添加した培地に移植し、30℃で
3日間通気撹拌培養を行った。培養終了液を平板用培地
[1当り、イースト・ニトローゲン・ベース(アミノ
酸フリー)6.7g,グルコース20g,L−ヒスチジン100mg,ア
デニン30mg,ウラシル30mg,寒天200g]にプレーティング
し、得られたコロニーについて修飾HBsAg P31の生産性
を調べ、表1の結果を得た。
Example 1 Modified HBsAg P31 protein producing recombinant Saccharomyces
Cerevisiae AH22R - / pGLD P31-RcT the 2l Erlenmeyer before were charged to the flask culture medium 1 (1 per glucose 100g,
Potassium monohydrogen phosphate 3g, L-asparagine 4g, L-histidine 100mg, magnesium sulfate 500mg, calcium chloride 330m
g, potassium iodide 0.1mg, ferrous sulfate 2.5mg, copper sulfate 0.4mg,
0.4 mg manganese sulfate, 0.2 m ammonium phosphomolybdate
g, zinc sulfate 3.1 mg, inositol 30 mg, thiamine 0.6 mg, pyridoxine 0.6 mg, calcium pantothenate 0.6 mg, niacin 0.6 mg, biotin 0.006 mg), incubate at 30 ° C for 3 days, and preculture 2.5 liters of a production medium [200 g of a sucrose, 2.5 g of sodium monohydrogen phosphate, 0.5 g of potassium dihydrogen phosphate, each containing 200 ml of a liquid in a 5 liter fermenter]
Ammonium sulfate 2g, magnesium sulfate 0.5g, calcium chloride 0.33g, ferrous sulfate 10mg, manganese sulfate 10mg, zinc sulfate
10mg, potassium iodide 0.1mg, inositol 90mg, thiamine hydrochloride 1.8mg, pyridoxine hydrochloride 1.8mg, nicotinic acid 1.8mg, calcium pantothenate 1.8mg, biotin 0.018mg]
In addition, L-histidine was 100 mg / l, 150 mg / l, 200 mg / l, 400 mg / l.
The cells were transplanted to each of the added culture mediums so as to obtain 1 l, and cultured under aeration and stirring at 30 ° C. for 3 days. The cultured solution was plated on a plate medium [yeast-nitrogen base (amino acid free): 6.7 g, glucose: 20 g, L-histidine: 100 mg, adenine: 30 mg, uracil: 30 mg, agar: 200 g]. The productivity of the modified HBsAg P31 was examined, and the results shown in Table 1 were obtained.

実施例2 実施例1の前培養培地のL−ヒスチジン濃度を100mg/
l(A培地)と400mg/l(B培地)にした2種類の培地を
用意し、サッカロミセス・セレビシエAH22R-/pGLD P31-
RcTを接種し、30℃で3日間培養したのち、それぞれの
培地で3日間ずつ継代を繰返し、修飾HBsAg P31の生産
性を調べ、表2の結果を得た。すなわち、A培地で継代
すると生産性が著しく低下したが、B培地で継代した場
合には、5代継代後も全く安定であった。
Example 2 The L-histidine concentration of the preculture medium of Example 1 was 100 mg /
l (A medium) and 400 mg / l 2 kinds of media were prepared with the (B medium), Saccharomyces cerevisiae AH22R - / pGLD P31-
After inoculating RcT and culturing at 30 ° C. for 3 days, subculture was repeated in each medium for 3 days, and the productivity of the modified HBsAg P31 was examined. The results in Table 2 were obtained. That is, when the cells were passaged in the A medium, the productivity was significantly reduced, but when the cells were passaged in the B medium, they were completely stable after the fifth passage.

実施例3 実施例1の前培養培地のL−ヒスチジン濃度を100mg/
l(A培地)と400mg/l(B培地)にした2種類の培地を
2l容フラスコに1ずつ用意し、生産培地も同じくL−
ヒスチジン濃度を100mg/l(A′培地)と400mg/l(B′
培地)にし50l容醗酵槽に20lずつ用意した。
Example 3 The L-histidine concentration of the preculture medium of Example 1 was 100 mg /
l (A medium) and 400 mg / l (B medium)
Prepare one by one in a 2 l flask, and use L-
The histidine concentration was 100 mg / l (A 'medium) and 400 mg / l (B'
Medium) in a 50-liter fermenter.

ヒトリゾチーム遺伝子発現プラスミドによる組換え体
サッカロミセス・セレビシエAH22R-/pGEL125株を前培養
培地(A,B培地)に接種し30℃で3日間培養した後、生
産培地A′培地にはA培地で培養した培養液を、B′培
地にはB培地で培養した培養液をそれぞれ移植した。50
l醗酵槽で通気撹拌条件で4日間培養した後、培養液を
生理食塩水で希釈しヒトリゾチーム発現判定寒天培地
[1当り、庶糖80g,L−アスパラギン5g,塩化カリウム
2g,L−ヒスチジン300mg,ヨウ化カリウム100μg,リン酸
2水素カリウム400mg,硫酸マグネシウム500mg,塩化カル
シウム330mg,硫酸第一鉄1.25mg,硫酸銅0.2gm,硫酸マン
ガン0.2mg,リンモリブデン酸アンモニウム0.1mg,硫酸亜
鉛1.55mg,イノシトール20mg,チアミン0.4mg,ピリドキシ
ン0.4mg,パントテン酸カルシウム0.4mg,ナイアシン0.4m
g,ビオチン0.004mg,グルコース10g,1M−トリス・マレイ
ン酸(pH6.5)25ml、ミクロコッカス・リゾダイクティ
カス5g,寒天20g]に塗布して30℃で5日間培養した後、
生育してきたコロニーの回りのプラークの有無により、
ヒトリゾチームの生産性を調べ、表3の結果を得た。
Human lysozyme gene expression plasmid by recombinant Saccharomyces cerevisiae AH22R - / pGEL125 strain preculture medium (A, B medium) was inoculated and cultured for 3 days at 30 ° C., the culture in A medium production medium A 'medium The obtained culture was transplanted to the B 'medium, and the culture was cultured in the B medium. 50
l After culturing for 4 days in a fermenter under aeration and agitation conditions, the culture solution was diluted with physiological saline to determine the expression of human lysozyme agar medium [per sucrose 80 g, L-asparagine 5 g, potassium chloride
2 g, L-histidine 300 mg, potassium iodide 100 μg, potassium dihydrogen phosphate 400 mg, magnesium sulfate 500 mg, calcium chloride 330 mg, ferrous sulfate 1.25 mg, copper sulfate 0.2 gm, manganese sulfate 0.2 mg, ammonium phosphomolybdate 0.1 mg , Zinc sulfate 1.55mg, inositol 20mg, thiamine 0.4mg, pyridoxine 0.4mg, calcium pantothenate 0.4mg, niacin 0.4m
g, biotin 0.004 mg, glucose 10 g, 1 M-tris-maleic acid (pH 6.5) 25 ml, Micrococcus rhizodyticus 5 g, agar 20 g], and cultured at 30 ° C. for 5 days.
Depending on the presence or absence of plaque around the growing colony,
The productivity of human lysozyme was examined, and the results in Table 3 were obtained.

発明の作用および効果 本発明によれば、酵母組換え体の培養中に生じるであ
ろう組換えプラスミドの宿主酵母からの脱落および組換
えプラスミドの自己組換えによる一部遺伝子の組換えプ
ラスミドからの脱落を抑制することができ、目的物質を
安定に生産することができる。
According to the present invention, according to the present invention, a recombinant plasmid which is likely to be generated during the cultivation of a yeast recombinant is dropped out of the host yeast and a part of the gene is removed from the recombinant plasmid by self-recombination of the recombinant plasmid. Dropout can be suppressed, and the target substance can be stably produced.

本発明の方法は、目的の有用物質を生産するための培
養および酵母組換え体の継代に有利に用いられる。
The method of the present invention is advantageously used for culturing to produce a useful substance of interest and subculture of yeast recombinants.

───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.6,DB名) C12N 15/00 - 15/90 C12N 1/00 - 1/21 BIOSIS(DIALOG) WPI(DIALOG)──────────────────────────────────────────────────続 き Continued on the front page (58) Fields surveyed (Int. Cl. 6 , DB name) C12N 15/00-15/90 C12N 1/00-1/21 BIOSIS (DIALOG) WPI (DIALOG)

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】組換えプラスミドを保持する酵母を、150m
g/l以上のヒスチジンを添加した培地で培養することを
特徴とする、宿主酵母内で組換えプラスミドを安定に保
持させる方法。
(1) A yeast containing a recombinant plasmid is
A method for stably maintaining a recombinant plasmid in a host yeast, comprising culturing in a medium supplemented with histidine of not less than g / l.
JP5472790A 1990-03-05 1990-03-05 How to maintain a stable plasmid Expired - Lifetime JP2850262B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5472790A JP2850262B2 (en) 1990-03-05 1990-03-05 How to maintain a stable plasmid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5472790A JP2850262B2 (en) 1990-03-05 1990-03-05 How to maintain a stable plasmid

Publications (2)

Publication Number Publication Date
JPH03254685A JPH03254685A (en) 1991-11-13
JP2850262B2 true JP2850262B2 (en) 1999-01-27

Family

ID=12978836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5472790A Expired - Lifetime JP2850262B2 (en) 1990-03-05 1990-03-05 How to maintain a stable plasmid

Country Status (1)

Country Link
JP (1) JP2850262B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2905342A4 (en) * 2012-10-03 2016-03-16 Kyowa Hakko Kirin Co Ltd METHOD FOR PREVENTING POLYPEPTIDE REDUCTION BY ADDING AMINO ACID TO A LIQUID CULTURE MEDIUM

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2905342A4 (en) * 2012-10-03 2016-03-16 Kyowa Hakko Kirin Co Ltd METHOD FOR PREVENTING POLYPEPTIDE REDUCTION BY ADDING AMINO ACID TO A LIQUID CULTURE MEDIUM
US9976163B2 (en) 2012-10-03 2018-05-22 Kyowa Hakko Kirin Co., Ltd Method for preventing reduction of polypeptide by adding amino acid to culture solution

Also Published As

Publication number Publication date
JPH03254685A (en) 1991-11-13

Similar Documents

Publication Publication Date Title
US4959317A (en) Site-specific recombination of DNA in eukaryotic cells
JPS61162168A (en) Aspergirus niger character converting system
JPH0543348B2 (en)
JPS61108390A (en) Dna fragment having autonomous duplicated arrangement, hybrid plasmid containing said fragment, e. coil subjected to conversion of character by said hybrid plasmid and production of said dna fragment
JPH05184352A (en) Method for expressing dissimilar gene in pichia pastoris yeast, expression vector and transforming microorganism
JPH0515435B2 (en)
JPS60199386A (en) Transformation method of Yarrowia lipolyteica
US5334512A (en) Fatty acid supplemented medium for recombinant production of human serum albumin by yeast
DE69233031T2 (en) YEAR PROMOTOR AND ITS USE
DE3789833T2 (en) Isolated phenylalanine dehydrogenase gene and method for producing phenylalanine dehydrogenase.
JP2850262B2 (en) How to maintain a stable plasmid
JPH08511952A (en) Medium for recombinant yeast growth
DE69120315T2 (en) Recombinant DNA expression vectors and DNA compositions encoding isopenicillin N epimerase activity
JP3133774B2 (en) Novel host-vector system
US5013650A (en) Increased fermentation yield of expressed protein
JPS60188072A (en) Recombinant dna, its preparation, escherichia coli containing the same, and preparation of lipase using thereof
DE68914620T2 (en) Process for the preparation of the restriction endonucklease PvuI.
JP2587764B2 (en) Method for producing N-acylneuraminic acid aldolase
KR930006117B1 (en) Medium for animal cell culture
JP2003500059A (en) Phage-dependent mass production of bioactive proteins and peptides
JPS58158197A (en) Preparation of inosine by fermentation process
JPH0511958B2 (en)
DE3689020T2 (en) Fermentation yield of expressed protein.
CN113493745B (en) Genetically engineered bacteria that produce cephalosporin C and their construction methods
Joh et al. Genetic mapping of the chromosomal replication origin of Salmonella typhimurium